Investigating the link between lung cancer, cachexia, and stress using PET imaging
The Role of 18F-FDG PET/CT in the Early Prediction of Cachexia in Lung Cancer Patients
This study is trying to see how lung cancer, weight loss, and stress are connected by looking at metabolic changes in 150 lung cancer patients using special imaging and tests.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Vienna Academic / other |
| Locations | 3 sites (Vienna and 2 other locations) |
| Trial ID | NCT05912465 on ClinicalTrials.gov |
What this trial studies
This prospective observational study aims to explore the relationship between cancer cachexia, psychological stress, and metabolic changes in 150 lung cancer patients. Participants will undergo comprehensive assessments, including medical history, physical examinations, laboratory tests, and PET-CT imaging to evaluate metabolic activity. The study will diagnose cancer cachexia based on weight loss, reduced food intake, and inflammation markers, while psychological stress will be assessed through questionnaires and biomarkers. The primary goal is to identify differences in metabolic activity between cachectic and non-cachectic patients, with secondary objectives focusing on brain activity and the interplay between stress, inflammation, and metabolism.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients aged 18 years or older with a confirmed diagnosis of lung cancer.
Not a fit: Patients with a history of other malignancies, severe comorbidities, or contraindications to PET imaging may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of cancer cachexia in lung cancer patients, potentially enhancing their quality of life and treatment outcomes.
How similar studies have performed: While the approach of using PET imaging to assess metabolic changes in cancer cachexia is innovative, similar studies have shown promise in understanding cachexia in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients aged 18 years or older. * Confirmed diagnosis of lung cancer. * Willingness to participate in the study and provide informed consent. * Ability to comply with study procedures and follow-up visits. Exclusion Criteria: * Previous history of any other malignancy within the last 5 years, excluding non-melanoma skin cancer. * Concurrent participation in another clinical trial involving an investigational product. * Known contraindications or intolerance to PET/CT imaging or fluorodeoxyglucose (FDG). * Presence of severe comorbidities that may interfere with study participation or affect the interpretation of results. * Pregnant or lactating women, or those planning to become pregnant during the study period. * Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the study.
Where this trial is running
Vienna and 2 other locations
- Medical University of Vienna — Vienna, Austria (Recruiting)
- University of Leipzig Medical Center — Leipzig, Germany (Not_yet_recruiting)
- AOUC Azienda Ospedaliero-Universitaria Careggi — Florence, Italy (Not_yet_recruiting)
Study contacts
- Principal investigator: Marcus Hacker, Prof. — Medical University of Vienna, Department of Radiology and Nuclear Medicine
- Study coordinator: Marcus Hacker, Prof., MD
- Email: marcus.hacker@meduniwien.ac.at
- Phone: +43 140400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.